<DOC>
	<DOCNO>NCT00727831</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , methotrexate leucovorin , work different way stop growth cancer cell , either kill cell stop dividing . Glucarpidase may help return level methotrexate blood safe range . Giving high-dose methotrexate together glucarpidase leucovorin may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose methotrexate give together glucarpidase leucovorin treat patient newly diagnose primary central nervous system lymphoma .</brief_summary>
	<brief_title>Methotrexate , Glucarpidase , Leucovorin Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine dose-limiting toxicity methotrexate ( MTX ) give combination glucarpidase patient newly diagnose primary CNS lymphoma ( PCNSL ) . - To determine incidence immediate reaction relate use glucarpidase patient . - To define safer , practical , simple regimen deliver multiple course high-dose MTX use glucarpidase 'short ' leucovorin calcium rescue patient . - To monitor quality life mental function therapy patient . Secondary - To use regimen platform phase III study PCNSL . - To record disease response , duration response , overall survival patient treat regimen . OUTLINE : This multicenter , dose-escalation study high-dose methotrexate ( HD-MTX ) . Patients receive HD-MTX IV 4 hour day 1 . Beginning 22 hour start HD-MTX , patient receive glucarpidase IV 15 minute day 2 follow leucovorin calcium orally IV day 2-7 . Treatment repeat every 14 day 6 course absence disease progression unacceptable toxicity . Within 2-4 week completion study treatment , patient achieve maximum response stratify accord age ( &lt; 60 year vs ≥ 60 year ) may undergo whole brain radiotherapy ( WBRT ) daily , 5 day week , 3 5 week . Patients undergo blood sample collection periodically assess glucarpidase antibody MTX level . Patients assess mucositis incidence severity periodically , complete quality life assessment use EORTC QLQ-30 questionnaire Mini-Mental State questionnaire baseline , , completion study . After completion study treatment , patient follow 6 week WBRT , every 3 month 1 year , every 4 month 1 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose primary CNS lymphoma ( PCNSL ) Previously untreated disease Diffuse large Bcell lymphoma histology Must clinically eligible receive standard 3 g/m² methotrexate outside trial No clinically significant effusion edema PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 03 Neutrophils ≥ 1 x 10^9/L Platelet count ≥ 100 x 10^9/L Bilirubin &lt; 1.5 time upper limit normal Glomerular filtration rate ( initially measure EDTA/isotope method ) ≥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion study therapy Exclusion criterion : HIV positivity Dementia neurological dysfunction consider due PCNSL Other serious uncontrolled medical condition Prior malignancy , except adequately treat nonmelanoma skin cancer carcinoma situ PRIOR CONCURRENT THERAPY : No prior cytotoxic chemotherapy No concurrent prophylactic antibiotic No concurrent cotrimoxazole</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>mucositis</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>